Navigation Links
Human stem cells predict efficacy of Alzheimer drugs

Why do certain Alzheimer medications work in animal models but not in clinical trials in humans? A research team from the University of Bonn and the biomedical enterprise LIFE & BRAIN GmbH has been able to show that results of established test methods with animal models and cell lines used up until now can hardly be translated to the processes in the human brain. Drug testing should therefore be conducted with human nerve cells, conclude the scientists. The results are published by Cell Press in the journal "Stem Cell Reports".

In the brains of Alzheimer patients, deposits form that consist essentially of beta-amyloid and are harmful to nerve cells. Scientists are therefore searching for pharmaceutical compounds that prevent the formation of these dangerous aggregates. In animal models, certain non-steroidal anti-inflammatory drugs (NSAIDs) were found to a reduced formation of harmful beta-amyloid variants. Yet, in subsequent clinical studies, these NSAIDs failed to elicit any beneficial effects.

"The reasons for these negative results have remained unclear for a long time", says Prof. Dr. Oliver Brstle, Director of the Institute for Reconstructive Neurobiology of the University of Bonn and CEO of LIFE & BRAIN GmbH. "Remarkably, these compounds were never tested directly on the actual target cells the human neuron", adds lead author Dr. Jerome Mertens of Prof. Brstle's team, who now works at the Laboratory of Genetics in La Jolla (USA). This is because, so far, living human neurons have been extremely difficult to obtain. However, with the recent advances in stem cell research it has become possible to derive limitless numbers of brain cells from a small skin biopsy or other adult cell types.

Scientists transform skin cells into nerve cells

Now a research team from the Institute for Reconstructive Neurobiology and the Department of Neurology of the Bonn University Medical Center together with colleagues from the LIFE & BRAIN GmbH and the University of Leuven (Belgium) has obtained such nerve cells from humans. The researchers used skin cells from two patients with a familial form of Alzheimer's Disease to produce so-called induced pluripotent stem cells (iPS cells), by reprogramming the body's cells into a quasi-embryonic stage. They then transformed the resulting so-called "jack-of-all-trades cells" into nerve cells.

Using these human neurons, the scientists tested several compounds in the group of non-steroidal anti-inflammatory drugs. As control, the researchers used nerve cells they had obtained from iPS cells of donors who did not have the disease. Both in the nerve cells obtained from the Alzheimer patients and in the control cells, the NSAIDs that had previously tested positive in the animal models and cell lines typically used for drug screening had practically no effect: The values for the harmful beta-amyloid variants that form the feared aggregates in the brain remained unaffected when the cells were treated with clinically relevant dosages of these compounds.

Metabolic processes in animal models differ from humans

"In order to predict the efficacy of Alzheimer drugs, such tests have to be performed directly on the affected human nerve cells", concludes Prof. Brstle's colleague Dr. Philipp Koch, who led the study. Why do NSAIDs decrease the risk of aggregate formation in animal experiments and cell lines but not in human neurons? The scientists explain this with differences in metabolic processes between these different cell types. "The results are simply not transferable", says Dr. Koch.

The scientists now hope that in the future, testing of potential drugs for the treatment of Alzheimer's disease will be increasingly conducted using neurons obtained from iPS cells of patients. "The development of a single drug takes an average of ten years", says Prof. Brstle. "By using patient-specific nerve cells as a test system, investments by pharmaceutical companies and the tedious search for urgently needed Alzheimer medications could be greatly streamlined".


Contact: Dr. Oliver Brüstle
University of Bonn

Related medicine news :

1. New drug prevents spread of human prostate cancer cells
2. Scientists solving the mystery of human consciousness
3. First targeted nanomedicine to enter human clinical studies
4. Edith Mitchell, M.D., FACP, named 2012 recipient of ASCO Humanitarian Award
5. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
6. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
7. IBN discovers human neural stem cells with tumor targeting ability
8. RANK protein promotes the initiation, progression and metastasis of human breast cancer
9. CNIO researchers describe new functions of cohesin relevant for human disease
10. New Clues to the Evolution of the Human Brain
11. Humanist funerals
Post Your Comments:
Related Image:
Human stem cells predict efficacy of Alzheimer drugs
(Date:11/30/2015)... ... November 30, 2015 , ... An ... directory is specialized and only includes chiropractic clinics in the US. , The ... trustworthy alternative health practitioner when back pain sets in. When people are experiencing ...
(Date:11/30/2015)... ... November 30, 2015 , ... In ... Halloween festivities, the Word of Life Christian Church of Flint, MI, hosted a ... a giant 1.25 ton pile of candy dubbed “Candy Mountain”. , A Forever ...
(Date:11/30/2015)... ... November 30, 2015 , ... During ... fundraising campaign to raise funds for its research, education, support, and advocacy efforts. ... organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also goes by ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... in Dallas, TX, on January 29 and 30, 2016. The course welcomes dental ... of their practices, to learn how to better succeed in the modern dental ...
(Date:11/30/2015)... ... November 30, 2015 , ... HemoTreat™ has announced that the ... ointment to its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s ... the comparison chart and ingredient list allows our customers to quickly see why, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... Free Press as a Top Workplace , among the ... work for in 2015. ... annually, based on employee surveys rating company leadership, career opportunities, ... based solely on employee feedback. The survey is conducted by ...
(Date:11/30/2015)...  IBA Molecular North America, Inc. (IBAMNA), a U.S. ... that as of January 1, 2016, it will do ... to rebrand the company reflects a refined vision for ... close relationship with Zevacor Molecular.  Both IBAMNA and Zevacor ... Peter Burke , Vice President Sales ...
(Date:11/30/2015)... 30, 2015 Baxalta Incorporated (NYSE: ... dedicated to delivering transformative therapies to patients ... today announced the launch and first shipments ... extended circulating half-life recombinant factor VIII (rFVIII) ... ADVATE [Antihemophilic Factor (Recombinant)]. The treatment was ...
Breaking Medicine Technology: